Sanofi/Bristol Score Another Victory Over Apotex In Plavix Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic drug maker is thwarted in latest attempt to resume clopidogrel sales.
You may also be interested in...
Generic Plavix Supply Is Dwindling, McKesson Says
Wholesaler forecasts little additional sales of clopidogrel through the remainder of the year.
Plavix "Irreparable Harm" Debated During Preliminary Injunction Appeal
Patent litigation case between Sanofi/Bristol and Apotex will follow in January.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.